Méhtestrák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• TP53 8
• PD-1 17
• HER2 13
• PTEN 3
• PI3K 7
• PD-L1 6
• mTOR 2
• AKT 2
• CTNNB1 1
• PIK3CA 6
• ARID1A 3
• BRCA1 2
• KRAS 4
• PARP 3
• VEGF 2
• CDK4/6 3
• ERK 0
• GLP-1 3
• STAT3 0
• TROP2 3
• BRCA2 1
• CTLA-4 2
• MAPK 0
• ESR1 0
• AR 0
• ATM 1
• AMPK 1
• AXL 2
• B7-H3 2
• COX-2 0
• FGFR 0
• IGF1R 0
• TIGIT 1
• BCL-2 0
• FTO 0
• GPX4 0
• HDAC 0
• HER3 1
• PALB2 1
• RAS 1
• BRAF 0
• EGFR 2
• EZH2 0
• JAK 0
• JNK 0
• KEAP1 1
• LAG-3 0
• MDM2 0
• MET 0
• MMP-9 0
• NLRP3 0
• PRAME 1
• PSMA 1
• SGLT2 1
• STING 0
• STK11 1
• APOE 0
• CD20 0
• CD47 0
• CDKN2A 0

6+ intézményből 6, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R61

  Ultrasound-guided Ovarian Tissue Graft generation Platform to improve fertility outcomes

  Atera Medical· Mountain View, Egyesült Államok· 377 257 USD awarded in fiscal year 2026· until 2028. jún.

• NIH NCI · U01

  Collaborative Modeling to Identify Strategies to Improve US Breast Cancer Outcomes in an Era of Innovation

  University of Wisconsin-Madison· Madison, Egyesült Államok· 1 839 480 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NINDS · R56

  The Mechanism of Trinucleotide Repeat Disease Expansions

  Ohio State University· Columbus, Egyesült Államok· 551 250 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R34

  Reinforcing the Cancer Prevention Potential of Aspirin in Lynch Syndrome (ReCAPP-LS): Development and Piloting of an Electronic Decision Support Tool

  Research Inst of Fox Chase Can Ctr· Philadelphia, Egyesült Államok· 314 079 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NCI · U01

  Comparative Modeling of Uterine Cancer

  Tufts Medical Center· Boston, Egyesült Államok· 1 270 995 USD awarded in fiscal year 2026· until 2031. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Continuous Estrogen Monitoring Patch (EstroPatch)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution 321 301 EUR· until 2030. máj.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  Dencatistat, a first-in-class, tumour-agnostic, orally available CTPS1 inhibitor to treat gynaecologic tumours (STP938)

  Step Pharma· Paris, Franciaország· EU contribution 2 499 991 EUR· until 2027. aug.

  The disease is named only in the funder's project summary, not in the title.

7 of 150 running projects, newest first. Listed amounts together: 105,9 M USD + 2,8 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  NCT05797168· AstraZeneca· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 8
• Organoids 3
• Mendelian Randomization Analysis 13
• CRISPR-Cas Systems 5
• Gene Expression Profiling 37
• Sequence Analysis, RNA 1
• Exome Sequencing 6
• Proteomics 17
• Metabolomics 7
• Mass Spectrometry 1
• Flow Cytometry 1
• Immunohistochemistry 85
• Liquid Biopsy 4
• Circulating Tumor DNA 9
• Xenograft Model Antitumor Assays 38
• Positron-Emission Tomography 4
• Magnetic Resonance Imaging 36
• Machine Learning 35
• Deep Learning 18
• Cohort Studies 82
• Genome-Wide Association Study 11

• A retrospective analysis of BCOR-immunohistochemistry positive uterine sarcomas: Clinical features and survival.

  J Cancer Res Ther, 2026. okt.

• Histopathological and immunohistochemical analyses do not indicate timing of prophylactic hysterectomy: a retrospective analysis of endometrial biopsies in Lynch syndrome carriers.

  Fam Cancer, 2026. okt.

• Immunohistochemical evaluation of androgen receptor expression in endometrial carcinoma and its clinicopathological significance.

  Diagn Pathol, 2026. szept.

• Association of immunohistochemically defined molecular subtypes with substantial lymphovascular space invasion in early-stage endometrial cancer: a single-center cohort of 575 patients.

  J Gynecol Oncol, 2026. szept.

• Diagnostic and Prognostic Roles of Universal Estrogen Receptor Testing in Endometrial Carcinoma.

  Surg Pathol Clin, 2026. aug.

• Folate Receptor Alpha (FRα/FOLR1) Immunohistochemical Expression Across Molecularly Classified Endometrial Carcinomas.

  Int J Gynecol Pathol, 2026. aug.

• Stage-dependent expression and nuclear localization of EZH2 in endometrial carcinogenesis: evidence from cell lines and human tissues.

  J Mol Histol, 2026. aug.

• Metastatic High-Grade Endometrioid Carcinoma to the Lung With Pilomatrix Carcinoma-Like Morphology: Potential for Misdiagnosis as Non-Small Cell Carcinoma.

  Am J Surg Pathol, 2026. júl.

• Molecular classification of endometrial carcinoma: clinical utility of an NGS panel with targeted detection of 116 cancer-related genes.

  Pathol Oncol Res, 2026. júl.

• SOX2 Can Support a Diagnosis of PiMHEC With Rare to Absent Ghost Cells and Can Distinguish PiMHEC From Its Most Problematic Mimickers.

  Int J Gynecol Pathol, 2026. júl.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.